STAAR Surgical shares fell about 10% on Friday, potentially the worst one-day drop since February 2025, even after the company reported preliminary second-quarter net sales exceeding $90 million, above the $89.4 million analyst consensus and more than double the prior-year period. Jefferies analyst Young Li noted management did not provide second-half guidance and continued to express caution, saying investors want guidance before becoming more constructive. Needham’s David Saxon wrote that the preannouncement lowers the bar for the second half but adds ambiguity, while BTIG’s Ryan Zimmerman cited similar concerns, pointing to seasonality in the Chinese market as a key overhang and the lack of full-year revenue guidance.
STAAR Surgical CompanyCompany reported Q2 sales beat but management did not provide second-half guidance, causing analyst uncertainty and a 10% stock drop.